| Patents for C07D 215 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems (27,676) |
|---|
| 07/21/2005 | WO2005066115A2 Disubstituted chalcone oximes having rarϝ retinoid receptor antagonist activity |
| 07/21/2005 | WO2005043124A3 Chiral 1,8-diarylnaphthalenes, methods of making them, and their use as sensors |
| 07/21/2005 | WO2005042712A3 Heterocyclic compounds and methods of making and using thereof |
| 07/21/2005 | WO2005033119A9 Supramolecular compounds and their use as antitumour and antiviral agents |
| 07/21/2005 | WO2004050609A8 Substituted ureas and carbamates |
| 07/21/2005 | US20050159480 Preparation of statins by reacting (trisubstituted phosphoranylidenecarbonyl)acetates with benzaldehydes, reduction with diamino-group 8 metal coordinates, condensation with 1-hydroxy-1-alkoxyethylenes, hydrolysis, and optionally converting the carboxy acid product into a salt or a lactone |
| 07/21/2005 | US20050159448 Aryl aniline derivatives as beta2 adrenergic receptor agonists |
| 07/21/2005 | US20050159447 Quinoline derivative anticarcinogenic compounds; based on herbicides |
| 07/21/2005 | US20050159446 of preparing 4-substituted quinoline compounds as intermediates in the manufacture of receptor tyrosine kinase inhibitors and intermediate compounds used in the methods thereof, wherein the 4-substituted quinoline compound has the following general formula (I): |
| 07/21/2005 | US20050159429 Novel crystalline forms of aripiprazole |
| 07/21/2005 | US20050159421 Ethylene diamine derivatives and their use as orexin-receptor antagonists |
| 07/21/2005 | DE10360154A1 New 2-(hetero)aryl-tetrahydroquinoline derivatives and 1,2,3,4-tetrahydro-1,5-naphthyridine derivatives are mitotic motor protein Eg5 inhibitors used as anticancer agents for treating carcinoma or leukemia |
| 07/21/2005 | CA2552090A1 Disubstituted chalcone oximes as selective agonists of rar.gamma. retinoid receptors |
| 07/21/2005 | CA2551294A1 Disubstituted chalcone oximes having rary retinoid receptor antagonist activity |
| 07/20/2005 | EP1554260A1 Aryloxyalkylamine derivatives as h3 receptor ligands |
| 07/20/2005 | EP1554249A2 1-pyridin-4-yl-urea derivatives |
| 07/20/2005 | EP1554243A1 Bicyclic benzamide compounds as histamine h3 receptor ligand useful in the treatment of neurological diseases |
| 07/20/2005 | EP1554239A2 Sulfonylamino-acetic acid derivatives and their use as orexin receptor antagonists |
| 07/20/2005 | CN1642931A Sulfonylamino-derivatives as novel inhibitors of histone deacetylase |
| 07/20/2005 | CN1642917A Non-peptide GnRH antagonists |
| 07/20/2005 | CN1642915A Benzamide derivatives useful as histone deacetylase inhibitors |
| 07/20/2005 | CN1642580A Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands |
| 07/20/2005 | CN1211369C L-amino acid acyl-(8-quinolyl) amine platinum (II) complex and prep. and use thereof |
| 07/20/2005 | CN1211331C Method for isomerisation of allyl alcohols |
| 07/19/2005 | US6919470 Aryl and heteroaryl sulfonates |
| 07/19/2005 | US6919353 Enzyme inhibitors of phosphordiesterase 4 having minimal side effects; antiinflammatory agents; antiallergens; asthma; neurodegenerative disorders; antidiabetic agents; pain; anti-tumor, -carcinogenic and -arthritic agents |
| 07/19/2005 | US6919347 Antidiabetic agents; antiinflammatory agents; analgesics; antiallergens |
| 07/19/2005 | US6919339 ABCA-1 elevating compounds |
| 07/19/2005 | US6919335 Heterocycles that are inhibitors of IMPDH enzyme |
| 07/14/2005 | WO2005064006A1 OPTICALLY ACTIVE, HETEROAROMATIC β-HYDROXY ESTERS, PROCESSES FOR THEIR PREPARATION FROM β-KETO ESTERS AND PROCESSES FOR THE PREPARATION OF THESE β-KETO ESTERS |
| 07/14/2005 | WO2005063713A1 Crystal of salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)amino-phenoxy)-7-methoxy-6-quinolinecarboxamide or of solvate thereof and processes for producing these |
| 07/14/2005 | WO2005063712A1 5-ht2 receptors modulators, their pharmaceuticals compositions and their use for the treatment of cardiovascular and muscle diseases |
| 07/14/2005 | WO2005063711A1 Crystal form of quinoline compound and process for its production |
| 07/14/2005 | WO2005063689A1 Benzamide derivative |
| 07/14/2005 | WO2005063244A1 Acidic quinoline derivatives and their use for the prevention and/or treatment of hyperglycaemia-related pathologies |
| 07/14/2005 | WO2005063239A1 3-(4-piperidine-1ylmethyl-phenyl)-propion acid-phenylamide-derivatives and related compounds used in the form of mch antagonists (melanine concentrating hormone) for treating eating disorders |
| 07/14/2005 | WO2005035514A3 Modulators of atp-binding cassette transporters containing cycloalkyl or pyranyl groups |
| 07/14/2005 | WO2005017185A3 HEPATOCYTE NUCLEAR FACTOR 4α MODULATOR COMPOUNDS |
| 07/14/2005 | US20050154230 Urea derivatives |
| 07/14/2005 | US20050154202 Substituted aryl amides |
| 07/14/2005 | US20050154013 Pressurised metered dose inhalers containing solutions of beta-2 agonists |
| 07/14/2005 | US20050154008 Aryl fused substituted 4-oxy-pyridines |
| 07/14/2005 | US20050153974 Heterocyclymethylpiperidines and -piperazines possessing affinity at 5ht-1 type receptors |
| 07/14/2005 | US20050153964 Novel compounds |
| 07/14/2005 | US20050153957 Beta2-adrenoceptor agonists |
| 07/14/2005 | US20050153942 Heterocyclic inhibitors of MEK and methods of use thereof |
| 07/14/2005 | US20050152981 jet crystallization utilizes two jet streams that strike each other head-on; streams carries a solution rich in the aripiprazole and the other carries an anti-solvent, such as water |
| 07/14/2005 | US20050152846 Hydrofluoroalkane (HFA) propellant and co-solvents; inhalants; storage stability; deep lung penetration |
| 07/14/2005 | CA2551552A1 5-ht2 receptors modulators, their pharmaceuticals compositions and their use for the treatment of cardiovascular and muscle diseases |
| 07/14/2005 | CA2551227A1 Acidic quinoline derivatives and their use for the prevention and/or treatment of hyperglycaemia-related pathologies |
| 07/14/2005 | CA2551050A1 Crystal form of quinoline compound and process for its production |
| 07/14/2005 | CA2550649A1 3-(4-piperidine-1ylmethyl-phenyl)-propion acid-phenylamide-derivatives and related compounds used in the form of mch antagonists (melanine concentrating hormone) for treating eating disorders |
| 07/14/2005 | CA2546981A1 Optically active, heteroaromatic .beta.-hydroxy esters, processes for their preparation from .beta.-keto esters and processes for the preparation of these .beta.-keto esters |
| 07/13/2005 | EP1553092A1 Aralkyl formyl-alkyl piperazine derivatives and their uses as cerebral nerve protective agent |
| 07/13/2005 | EP1551829A2 Novel compounds with antibacterial activity |
| 07/13/2005 | EP1551807A1 Improved reagents for n-amination |
| 07/13/2005 | EP1551798A1 Novel sulphones for inhibition of gamma secretase |
| 07/13/2005 | EP1448529B1 Sulfone derivatives suitable for the treatment of autoimmune diseases and allergies |
| 07/13/2005 | EP1161415B1 N-cyanomethylamides as protease inhibitors |
| 07/13/2005 | CN1639130A Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same |
| 07/13/2005 | CN1639119A Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors |
| 07/13/2005 | CN1639096A Process for producing trans-4-amino-1-cyclohexanecarboxylic acid derivative |
| 07/13/2005 | CN1638757A 组织蛋白酶半胱氨酸蛋白酶抑制剂 Cathepsin cystatin |
| 07/13/2005 | CN1638730A Formoterol superfine formulation |
| 07/13/2005 | CN1638729A Pressurised metered dose inhalers containing solutions of beta-2 agonists |
| 07/13/2005 | CN1636986A Benzophenones as inhibitors of reverse transcriptase |
| 07/13/2005 | CN1636985A Benzophenones as inhibitors of reverse transcriptase |
| 07/13/2005 | CN1636984A Benzophenones as inhibitors of reverse transcriptase |
| 07/13/2005 | CN1636976A Mutilin derivatives and their use as antibacterials |
| 07/13/2005 | CN1636597A Compounds for the treatment of female sexual dysfunction |
| 07/13/2005 | CN1210263C N-hydroxy-2-(alkyl, aryl or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors |
| 07/12/2005 | US6916957 Antiinflammatory agents; antihistamines; antiallergens |
| 07/12/2005 | US6916831 Oxo acids and salts such as 2-Phenyl-4-quinolone-8-acetic acid, used for prophylaxis of cancers; antitumor agents |
| 07/12/2005 | US6916812 Dietetic agents |
| 07/12/2005 | CA2319542C The treatment of sexual dysfunction in certain patient groups |
| 07/12/2005 | CA2094494C A 4-quinolone antibiotic compound as gamma ray scintigraphy diagnostic imaging agent |
| 07/07/2005 | WO2005061475A2 Ornithine derivatives as prostaglandin e2 agonists or antagonists |
| 07/07/2005 | WO2005061459A1 Biaryl sulfonamides and methods for using same |
| 07/07/2005 | WO2005060963A1 Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity |
| 07/07/2005 | WO2005060748A1 Fungicide |
| 07/07/2005 | WO2005060456A2 Method for treating adamts-5-associate disease |
| 07/07/2005 | WO2005047258A3 Methods and compositions for selectin inhibition |
| 07/07/2005 | WO2005047257A3 Methods and compositions for selectin inhibition |
| 07/07/2005 | WO2005042498A3 4-amino (aza) quinoline derivatives as capsaicin receptor agonists |
| 07/07/2005 | WO2005034869A3 Compounds and compositions as protein kinase inhibitors |
| 07/07/2005 | US20050148777 (2R)-6-chloro-7-isobutyl-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid; cyclooxygenase-2 mediated disorders |
| 07/07/2005 | US20050148648 Cystic fibrosis transmembrane conductance regulator; ABC transporter mediated diseases like cystic fibrosis; 5-methoxy-N-((1-(3,4-dimethoxyphenyl)-cyclohexyl)methyl)benzofuran-2-carboxamide; or sulfonamide analogs; chloride or bicarbonate channel modulators |
| 07/07/2005 | US20050148631 Modulation of steroid enzymes in mammals as antidiabetic agents, for treatment of obesity, vision defects, lowering fats in blood, for treatment of osteoporosis, tuberculosis or atherosclerosis in mammals |
| 07/07/2005 | US20050148627 Benzopyran compounds for use in the treatment and prevention of inflammation related conditions |
| 07/07/2005 | US20050148626 Novel thromodulin expression promoters |
| 07/07/2005 | US20050148605 Modulation of protein tyrosine kinases for treatment of diseases with prodrugs |
| 07/07/2005 | US20050148595 heterocylcyclic amines used for treating or preventing conditions ameliorated by monoamine reuptake such as vasomotor symptoms, sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders |
| 07/07/2005 | US20050148590 4-[3-Hydroxyimino-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-propenyl]-benzoic acid; emphysema; respiratory system and skin disorder; acne and psoriasis; side effect reduction; improved pharmacology |
| 07/07/2005 | US20050148581 Quinolines; 1-(6-bromo-2-methoxy-quinolin-3-yl)-4-dimethylamino-2-naphthalen-1-yl-1-phenyl-butan-2-ol; Mycobacterium tuberculosis, M. bovis, M. avium and M. marinum; reduces the total length of treatment and the frequency of drug administration; multi-drug and antibiotic resistance |
| 07/07/2005 | CA2550958A1 Ornithine derivatives as prostaglandin e2 agonists or antagonists |
| 07/07/2005 | CA2549651A1 Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity |
| 07/07/2005 | CA2548513A1 Biaryl sulfonamides and methods for using same |
| 07/07/2005 | CA2547575A1 Method for treating adamts-5-associated disease |
| 07/06/2005 | EP1549613A1 Sulfonamides having antiangiogenic and anticancer activity |
| 07/06/2005 | CN1636004A Process for the manufacture of hmg-coa reductase inhibitory mevalonic acid derivatives |